Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Roivant Sciences stock

ROIV
BMG762791017
A3C4MS

Price

0
Today +/-
-0
Today %
-0 %

Roivant Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Roivant Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Roivant Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Roivant Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Roivant Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Roivant Sciences Stock Price History

DateRoivant Sciences Price
12/24/20240 undefined
12/23/20240 undefined
12/20/20240 undefined
12/19/20240 undefined
12/18/20240 undefined
12/17/20240 undefined
12/16/20240 undefined
12/13/20240 undefined
12/12/20240 undefined
12/11/20240 undefined
12/10/20240 undefined
12/9/20240 undefined
12/6/20240 undefined
12/5/20240 undefined
12/4/20240 undefined
12/3/20240 undefined
12/2/20240 undefined
11/29/20240 undefined
11/27/20240 undefined
11/26/20240 undefined

Roivant Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Roivant Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Roivant Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Roivant Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Roivant Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Roivant Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Roivant Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Roivant Sciences’s growth potential.

Roivant Sciences Revenue, EBIT and net profit per share

DateRoivant Sciences RevenueRoivant Sciences EBITRoivant Sciences Net Income
2030e0 undefined0 undefined0 undefined
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
20240 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined

Roivant Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2019202020212022202320242025e2026e2027e2028e2029e2030e
000000000000
------------
------------
000000000000
000000000000
------------
000000000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Roivant Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Roivant Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2019202020202021202220232024
             
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
             
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Roivant Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Roivant Sciences's financial health and stability.

Assets

Roivant Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Roivant Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Roivant Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Roivant Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201920202020202120222023
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
000000
------
000000
000000
000000
000000

Roivant Sciences stock margins

The Roivant Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Roivant Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Roivant Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Roivant Sciences's sales revenue. A higher gross margin percentage indicates that the Roivant Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Roivant Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Roivant Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Roivant Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Roivant Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Roivant Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Roivant Sciences Margin History

Roivant Sciences Gross marginRoivant Sciences Profit marginRoivant Sciences EBIT marginRoivant Sciences Profit margin
2030e0 %0 %0 %
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %

Roivant Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Roivant Sciences earnings per share therefore indicates how much revenue Roivant Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Roivant Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Roivant Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Roivant Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Roivant Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Roivant Sciences Revenue, EBIT and net profit per share

DateRoivant Sciences Sales per ShareRoivant Sciences EBIT per shareRoivant Sciences Earnings per Share
2030e0 undefined0 undefined0 undefined
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
20240 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined

Roivant Sciences business model

Roivant Sciences Ltd is a biopharmaceutical company based in Basel, Switzerland. It was founded in 2014 by Vivek Ramaswamy, a former hedge fund manager. The company's idea was to develop "orphan molecules," which are drug compounds that have not been further developed by large pharmaceutical companies for various reasons. Roivant Sciences' business model is based on identifying therapy areas with high unmet medical needs. It then collaborates with academic institutions and other partners to search for orphan molecules that could be potentially interesting for these therapy areas. The molecules are further developed in the company's internal research and development laboratories. Roivant Sciences has established seven different subsidiary companies through its innovative approach to drug development and acquisition of other companies. Some of the most well-known subsidiaries include Axovant Sciences, Dermavant Sciences, Enzyvant Therapeutics, and Myovant Sciences. Each subsidiary of Roivant Sciences focuses on specific therapy areas. For example, Axovant Sciences focuses on developing therapies for neurological diseases such as Parkinson's and Alzheimer's, while Dermavant Sciences focuses on dermatology and Enzyvant Therapeutics concentrates on rare genetic diseases. Roivant Sciences has also raised a considerable amount of capital to finance its various companies. In 2017, the company raised $1.1 billion, expanding its presence in the global healthcare market. Products developed by Roivant Sciences' subsidiaries include Axovant's Nelotanserin, a potential medication for hallucinations and nightmares in Parkinson's patients, as well as Myovant's Leuprolide, a medication for treating prostate cancer. The company also has a partnership with Dartmouth College to advance research and development in neuroscience. The partnership aims to identify "specific molecular targets" for developing treatments for neurodegenerative diseases. In summary, Roivant Sciences Ltd is an innovative biopharmaceutical company that develops orphan molecules and specializes in various therapy areas. Its subsidiaries develop products for a range of diseases, from Alzheimer's to prostate cancer and rare genetic disorders. The company has raised a significant amount of capital to finance its operations and collaborates with academic institutions to advance its research and development. Roivant Sciences is one of the most popular companies on Eulerpool.com.

Roivant Sciences SWOT Analysis

Strengths

1. Strong Research and Development capabilities, enabling development of innovative drugs and therapies.

2. Well-established partnerships with leading pharmaceutical companies, providing access to resources, expertise, and potential collaborations.

3. Diverse portfolio of drug candidates across various therapeutic areas, reducing dependency on a single product.

Weaknesses

1. Relatively small market presence compared to larger pharmaceutical companies, limiting brand recognition and market share.

2. High dependence on external sources for funding research and development activities, making the company vulnerable to changes in funding availability.

3. Limited manufacturing capabilities, potentially impacting the speed and efficiency of drug production.

Opportunities

1. Growing demand for innovative and personalized healthcare solutions, creating opportunities for Roivant Sciences Ltd to capitalize on its R&D expertise.

2. Expansion into emerging markets with favorable regulatory environments, allowing for increased market penetration.

3. Potential collaborations with academic institutions and research organizations to further enhance R&D capabilities.

Threats

1. Intense competition within the pharmaceutical industry, with larger players having significant resources and established market positions.

2. Stringent regulatory requirements and lengthy approval processes, posing challenges and delays in bringing new drugs to market.

3. Uncertainty surrounding healthcare policies and reimbursement systems, potentially impacting the demand and pricing of drugs.

Roivant Sciences Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Roivant Sciences Revenue by Segment

Segmente20242023
Product revenue, net75.06 M U00128.01 M U001
Represents the license, milestone, and other revenue24.9 M U00133.27 M U001
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Roivant Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Roivant Sciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Roivant Sciences shares outstanding

The number of shares was Roivant Sciences in 2023 — This indicates how many shares 712.79 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Roivant Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Roivant Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Roivant Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Roivant Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Roivant Sciences stock splits

In Roivant Sciences's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Roivant Sciences.

Roivant Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240 0  (-18.59 %)2025 Q2
6/30/20240 0  (145.25 %)2025 Q1
3/31/20240 0  (38.59 %)2024 Q4
12/31/20230 0  (8.09 %)2024 Q3
9/30/20230 0  (-27.11 %)2024 Q2
6/30/20230 0  (-25.16 %)2024 Q1
3/31/20230 0  (45.73 %)2023 Q4
12/31/20220 0  (-24.27 %)2023 Q3
9/30/20220 0  (0.92 %)2023 Q2
6/30/20220 0  (-45.54 %)2023 Q1
1
2

Eulerpool ESG Scorecard© for the Roivant Sciences stock

Eulerpool World ESG Rating (EESG©)

29/ 100

🌱 Environment

13

👫 Social

34

🏛️ Governance

38

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Roivant Sciences shareholders

%
Name
Stocks
Change
Date
14.12864 % Dexcel Pharma Technologies, Ltd.102,849,44307/1/2024
9.77022 % SB Investment Advisers (UK) Limited71,122,349-239,0397/1/2024
9.52936 % Viking Global Investors LP69,368,961213,1157/1/2024
9.16543 % QVT Financial LP66,719,77907/1/2024
7.33999 % Ramaswamy (Vivek)53,431,4264,502,0007/1/2024
6.39483 % Fidelity Management & Research Company LLC46,551,14611,210,5836/30/2024
4.27861 % BlackRock Institutional Trust Company, N.A.31,146,160-956,7286/30/2024
3.65930 % Morgan Stanley Investment Management Inc. (US)26,637,886-2,046,9176/30/2024
3.31702 % Sukhatme (Mayukh)24,146,23018,836,5477/26/2024
3.15956 % Rubric Capital Management LP23,000,0003,000,0006/30/2024
1
2
3
4
5
...
10

Roivant Sciences Executives and Management Board

Dr. Mayukh Sukhatme

(47)
Roivant Sciences President, Chief Investment Officer
Compensation 49.05 M

Mr. Matthew Gline

(39)
Roivant Sciences Chief Executive Officer, Director (since 2017)
Compensation 48.98 M

Dr. Eric Venker

(36)
Roivant Sciences President, Chief Operating Officer
Compensation 48.49 M

Ms. Melissa Epperly

(46)
Roivant Sciences Independent Director
Compensation 654,017

Mr. Ilan Oren

(39)
Roivant Sciences Independent Chairman of the Board
Compensation 403,528
1
2
3

Most common questions regarding Roivant Sciences

What values and corporate philosophy does Roivant Sciences represent?

Roivant Sciences Ltd represents a commitment to innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on transforming the biopharmaceutical industry, Roivant Sciences aims to address unmet medical needs by developing and commercializing novel therapies. The company values scientific excellence and prioritizes the advancement of groundbreaking technologies and therapeutics. Roivant Sciences also strives for transparency, integrity, and respect in all its interactions, forming strategic partnerships with leading healthcare organizations and experts worldwide. Through its core values and corporate philosophy, Roivant Sciences is dedicated to improving healthcare outcomes and enhancing the overall well-being of patients.

In which countries and regions is Roivant Sciences primarily present?

Roivant Sciences Ltd primarily operates in various countries and regions globally. As a biopharmaceutical company, Roivant Sciences Ltd has a significant presence in the United States, where its headquarters are located. The company has also expanded its operations to other regions, including Europe, Asia, and Latin America. With a focus on developing and commercializing innovative therapies, Roivant Sciences Ltd continues to establish a strong international footprint, leveraging its expertise to address patients' unmet needs in different markets worldwide.

What significant milestones has the company Roivant Sciences achieved?

Roivant Sciences Ltd has achieved significant milestones in its journey. With a focus on innovative healthcare solutions, the company has made noteworthy achievements. One of the notable milestones is the successful approval of its flagship product, [Company Name], by regulatory authorities. Additionally, Roivant Sciences Ltd has established key strategic partnerships with leading pharmaceutical companies, further enhancing its global presence and research capabilities. The company's commitment to advancing medical research and development is exemplified by its continuous efforts in pioneering groundbreaking therapies and treatments. As a result, Roivant Sciences Ltd has positioned itself as a trusted and trailblazing player in the healthcare industry.

What is the history and background of the company Roivant Sciences?

Roivant Sciences Ltd is a well-established pharmaceutical company with a rich history and background. Founded in 2014, Roivant Sciences has quickly gained recognition for its innovative approach to developing and commercializing transformative drugs. Headquartered in Basel, Switzerland, the company focuses on harnessing advanced technologies and data-driven solutions to tackle unmet medical needs. With a strong emphasis on strategic partnerships and collaborations, Roivant Sciences has attracted global attention for its success in bringing novel therapies to market. As a leading player in the healthcare industry, Roivant Sciences continues to revolutionize the treatment landscape, earning a reputation for its commitment to improving patients' lives and addressing critical healthcare challenges.

Who are the main competitors of Roivant Sciences in the market?

The main competitors of Roivant Sciences Ltd in the market are Actinium Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., Akorn, Inc., and Alkermes plc.

In which industries is Roivant Sciences primarily active?

Roivant Sciences Ltd is primarily active in the pharmaceutical and healthcare industries. With a focus on developing and commercializing innovative therapies, Roivant Sciences Ltd aims to improve patient care and address unmet medical needs. By leveraging their unique approach to drug discovery and development, the company strives to make a significant impact in various therapeutic areas. Through strategic partnerships and a robust pipeline of investigational drug candidates, Roivant Sciences Ltd continues to drive advancements in healthcare with its commitment to innovation and improving patient outcomes.

What is the business model of Roivant Sciences?

Roivant Sciences Ltd has a unique business model focused on creating and developing innovative biopharmaceutical companies. They identify and acquire promising drug candidates from research organizations and pharmaceutical companies, and then allocate resources to further develop and commercialize these potential therapies. By operating a centralized infrastructure, Roivant provides expertise in areas such as clinical development, regulatory affairs, and commercialization, enabling their subsidiary companies to focus on scientific advancements. Their mission is to transform the traditional drug development process and bring important therapies to patients in need. Roivant Sciences Ltd is driven by a commitment to improve healthcare options and deliver value to their stakeholders.

What is the P/E ratio of Roivant Sciences 2024?

The P/E ratio cannot be calculated for Roivant Sciences at the moment.

What is the P/S ratio of Roivant Sciences 2024?

The P/S cannot be calculated for Roivant Sciences currently.

What is the Quality Investing of Roivant Sciences?

The Quality Investing for Roivant Sciences is 3/10.

What is the revenue of Roivant Sciences 2024?

The revenue cannot currently be calculated for Roivant Sciences.

How high is the profit of Roivant Sciences 2024?

The profit cannot currently be calculated for Roivant Sciences.

What is the business model of Roivant Sciences

Roivant Sciences Ltd is a global biotech company headquartered in Basel, Switzerland. They focus on developing innovative therapies to address unmet medical needs of people worldwide. Roivant Sciences specializes in creating "Vants," separate operating subsidiaries that specialize in specific therapy areas. They identify specific clinical needs where there is no suitable therapy available and then establish a specific Vant dedicated to the development of therapies in that area. Some of Roivant Sciences' Vants include Axovant, which focuses on developing therapies for neurological diseases such as Alzheimer's and dementia. Enzyvant is dedicated to developing new treatments for rare, severe diseases, particularly for patients where treatment is no longer possible due to the absence of existing therapies. Myovant, another Vant of Roivant Sciences, focuses on developing therapies for women's health conditions such as endometriosis and infertility. Roivant Sciences drives the development of innovative therapies through partnerships and spin-offs of existing companies, and expands its therapeutic focus through strategic acquisitions. For example, in 2019, Roivant acquired Silicon Therapeutics, specializing in computer-assisted drug modeling. In addition to its Vants, Roivant Sciences also operates data prediction models through its Roivant Digital division and utilizes artificial intelligence and machine learning to discover new molecules and therapeutic approaches. These technologies complement the work of the company's Vants and enable faster and more efficient therapy development. Overall, Roivant Sciences has focused on developing therapies for diseases with high medical necessity. At the same time, the company strives to accelerate the development of new therapies by promoting collaboration between different disciplines such as biotechnology, software development, and data analysis. As the demand for novel therapeutic options remains high, Roivant Sciences is well positioned to achieve further groundbreaking developments in the industry in the coming years.

What is the Roivant Sciences dividend?

Roivant Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does Roivant Sciences pay dividends?

The dividend cannot currently be calculated for Roivant Sciences or the company does not pay out a dividend.

What is the Roivant Sciences ISIN?

The ISIN of Roivant Sciences is BMG762791017.

What is the Roivant Sciences WKN?

The WKN of Roivant Sciences is A3C4MS.

What is the Roivant Sciences ticker?

The ticker of Roivant Sciences is ROIV.

How much dividend does Roivant Sciences pay?

Over the past 12 months, Roivant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Roivant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Roivant Sciences?

The current dividend yield of Roivant Sciences is .

When does Roivant Sciences pay dividends?

Roivant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Roivant Sciences?

Roivant Sciences paid dividends every year for the past 0 years.

What is the dividend of Roivant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Roivant Sciences located?

Roivant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Roivant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Roivant Sciences from 12/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/25/2024.

When did Roivant Sciences pay the last dividend?

The last dividend was paid out on 12/25/2024.

What was the dividend of Roivant Sciences in the year 2023?

In the year 2023, Roivant Sciences distributed 0 USD as dividends.

In which currency does Roivant Sciences pay out the dividend?

The dividends of Roivant Sciences are distributed in USD.

All fundamentals about Roivant Sciences

Our stock analysis for Roivant Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roivant Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.